Photo from wikipedia
BRAF mutation status is a critical predictive and prognostic biomarker in guiding management of unresectable and metastatic melanoma.1 We recently observed a case of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic… Click to show full abstract
BRAF mutation status is a critical predictive and prognostic biomarker in guiding management of unresectable and metastatic melanoma.1 We recently observed a case of BRAF V600E-mutated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) intermixed with BRAF V600E wild-type melanoma reported to harbor BRAF V600E mutation on molecular testing. Our observation underscores the importance of appropriate tumor selection for molecular studies and knowledge of mutational status of co-existing tumors. This article is protected by copyright. All rights reserved.
Journal Title: Journal of Cutaneous Pathology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!